{'fraction_non_alphanumeric': 0.024630541871921183, 'fraction_numerical': 0.0049261083743842365, 'mean_word_length': 6.004926108374384, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors

Increased transplant activity calls for improved stem cell collection, especially when peripheral blood is the preferred source of haematopoietic progenitor cells (HPCs). Plerixafor is a bicyclam molecule that mobilizes CD34+ cells by reversibly disrupting CXCR4‐CXCL12‐supported HPC retention. Plerixafor is given with granulocyte colony‐stimulating factor (G‐CSF) to help harvest autologous CD34+ cells for transplantation when mobilization with G‐CSF fails. Mobilization protocols with the same doses of plerixafor and G‐CSF have been used off‐label in healthy allogeneic donors, with equal success and scarce side effects, both in adult and paediatric patients. Plerixafor has also been used as a sole mobilization agent. Plerixafor alone or coupled with G‐CSF might lead to harvesting distinct cellular populations conferring improved engraftment properties and increased survival. Those characteristics might make plerixafor an especially attractive mobilization agent, particularly for non‐related donations. However, available data are limited, and long‐term follow‐up is needed to clarify the best scenario for using plerixafor with or without G‐CSF in healthy donors. In this review, we will summarize the evidence supporting this practice, highlighting the practical aspects and providing clues for an expanded use of plerixafor.